After four years of collaborative research activities towards the development of a broadly reactive influenza vaccine, the European Commission-funded project EDUFLUVAC will be concluded by the end of October 2017. The EDUFLUVAC partners met for the final project meeting on 09-10 October in Brussels, Belgium to review the results generated and plan for future activities.
Promising pre-clinical results in different animal models have been obtained, but more research is needed to optimise the strategy undertaken by the consortium, which is based on the Epitope Dilution Phenomenon and the use of baculovirus-derived virus-like particles. During the meeting, several strategies have been discussed in order to secure future funding and have the possibility to continue working together on the EDUFLUVAC vaccine concept. The project partners have demonstrated an admirable collaboration and cooperative spirit throughout the whole project duration. Great efforts have been put in order to complete the research activities effectively and on time.